Sheila L Burgard

US Patent:

59981504, Dec 7, 1999

Filed:

Oct 1, 1996

Appl. No.:

8/723581

Inventors:

John Nicholas Whitaker - Birmingham AL
Robert David Kachelhofer - Birmingham AL
Beverly Ann Layton - Birmingham AL
Edwin Luther Bradley - Birmingham AL
Sheila Loughran Burgard - Lake Bluff IL
Anthony Thomas Reder - Oak Park IL
Wendy Jean Morrison - Vancouver, CA
Guojun Zhao - Vancouver, CA
Donald Winston Paty - Vancouver, CA

Assignee:

UAB Research Foundation - Birmingham AL

International Classification:

G01N 3353
G01N 33566
G01N 33567
G01N 33536

US Classification:

435 71

Abstract:

The present invention provides a method of determining the status of a multiple sclerosis patient, i. e. , predicting the transition from a status of relapsing-remitting to a progressive phase of multiple sclerosis, comprising the step of measuring the levels of urinary myelin basic protein-like material in the patient. The present invention also provides a method of determining the amount of lesions and total lesion area of a multiple sclerosis patient, comprising the step of measuring the levels of urinary myelin basic protein-like material in the patient. Further provided is a method of monitoring myelination in a developing child, comprising the step of: measuring the levels of myelin basic protein-like material in the urine of said child.

US Patent:

62844733, Sep 4, 2001

Filed:

Oct 6, 1999

Appl. No.:

9/412851

Inventors:

John Nicholas Whitaker - Birmingham AL
Robert David Kachelhofer - Birmingham AL
Edwin Luther Bradley - Birmingham AL
Sheila Loughran Burgard - Lake Bluff IL
Beverly Ann Layton - Birmingham AL
Anthony Thomas Reder - Oak Park IL
Wendy Jean Morrision - Vancouver, CA
Guojun Zhao - Burnaby, CA
Donald Winston Paty - Vancouver, CA
Ligong Cao - Birmingham AL
Lori Coward - Birmingham AL
Patricia L. Jackson - Moody AL
Marion Kirk - Birmingham AL

Assignee:

UAB Research Foundation - Birmingham AL

International Classification:

G01N 3353
G01N 33566
G01N 33567
G01N 33536

US Classification:

435 71

Abstract:

The present invention provides a method of determining the status of a multiple sclerosis patient, i. e. , predicting the transition from a status of relapsing-remitting to a progressive phase of multiple sclerosis, comprising the step of measuring the amount of urinary p-cresol sulfate in the patient. The present invention also provides a method of determining the amount of lesions and total lesion area of a multiple sclerosis patient, comprising the step of measuring the amount of urinary p-cresol sulfate in the patient. Further provided is a method of monitoring myelination in a developing child, comprising the step of: measuring the amount of p-cresol sulfate in the urine of said child.